Healthcare
Advicenne: Net Revenue for the First Half of 2026 Driven by Reimbursement of Sibnayal® and Likozam® in France
PARIS, July 16, 2026--Regulatory News: Advicenne S.A. ("Advicenne" or the "Company") (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, today announces its net revenue for the first half of 2026, more than doubled to €2.7 million, the first one reported without the significant negative impact of the early access clawbacks. The reported revenue does not incl
About this update from Advicenne Sa
PARIS, July 16, 2026 --( BUSINESS WIRE )--Regulatory News: Advicenne S.A. ("Advicenne" or the "Company") (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, today announces its net revenue for the first half of 2026, more than doubled to €2.7 million, the first one reported without the significant negative impact of the early access clawbacks. The reported revenue does not include royalties to be received from its commercial partners on Sibnayal®'s sales. The very significant increase in activity over the past half-year is explained by the pricing agreements for both Sibnayal® and Likozam® reached during the period. These agreements put an end to the early access rebates (clawback) which, as a reminder, amounted to €1.6 million in the first half of 2025. * :including early access rebate impact Since Sibnayal® and Likozam® gained reimbursement in France, sales of both products are accelerating, growing by 41% and 13% respectively in volume, reflecting the enlarged and easier access to treatments. Lastly, estimated in-market Sibnayal® sales across all markets where it is marketed totaled €6.6 million in the first half of 2026, up 27% compared with the first half of 2025, reflecting the steady increase in the number of patients treated. The royalties associated with these sales will be received by Advicenne during the third quarter of 2026. As of the date of this press release, the Company has a cash runway through the second quarter of 2027, thanks to the bond financing announced on June 22, as part of the safeguard proceedings ("Procédure de sauvegarde"). ABOUT ADVICENNE Advicenne (Euronext Growth Paris ALDVI - FR0013296746) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU, GB, KSA and UAE, and has been filed for a US NDA. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022.